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Abstract
The Cardiac Lipid Panel (CLP) is a novel panel of metabolomic biomarkers that has previously shown to
improve the diagnostic and prognostic value for CHF patients. Several prognostic scores have been
developed for cardiovascular disease (CVD) risk, but their use is limited to speci c populations and
precision is still inadequate. We compared a risk score using the CLP plus NT-proBNP to three commonly
used risk scores: The Seattle Heart Failure Model (SHFM), Framingham Risk Score (FRS), and MetaAnalysis Global Group in Chronic Heart Failure (MAGGIC) score. We included 280 elderly CHF patients
from the Cardiac Insu ciency Bisoprolol Study in Elderly (CIBIS-ELD) trial. Cox Regression and
hierarchical cluster analysis was performed. Integrated area under the curves (IAUC) was used as
criterium for comparison. The mean (SD) follow-up period was 81 (33) months, and 95 (34%) subjects
met the primary endpoint. The IAUC for FRS was 0.53, SHFM 0.61, MAGGIC 0.68, and CLP 0.78. Subjects
were partitioned into three risk clusters: low, moderate, high with the CLP score showing the best ability to
group patients into their respective risk cluster. A risk score composed of a novel panel of metabolite
biomarkers plus NT-proBNP outperformed other common prognostic scores in predicting 10-year
cardiovascular death in elderly ambulatory CHF patients. This approach could improve the clinical risk
assessment of CHF patients.

Introduction
The prevalence of chronic heart failure (CHF) in the western world continues to increase, especially in
patients older than 65 years [1]. CHF is a major burden on the health care system and is associated with
high morbidity and mortality, including a poor quality of life [2]. An important aspect of CHF management
is to ensure that clinicians and patients with CHF have the necessary knowledge and resources to make
the best health decisions. A prognostic model is one such resource, de ned as a formal combination of
multiple predictors from which risks of a speci c outcome can be calculated for individual patients.
Prognostic models are abundant in the literature, and the most popular ones include the SHFM (Seattle
Heart Failure Model), FRS (Framingham Risk Score), and MAGGIC (Meta-analysis Global Group in Chronic
Heart Failure). The SHFM score is the most thoroughly validated and contains the most predictor
variables of the three [3]. The MAGGIC score [4] was developed from a dataset of over 39,000 patients
across 30 studies and validated on more than 60,000 patients using 2 large CHF cohorts [5, 6]. The FRS
score was developed as a sex-speci c risk score that can be conveniently used to calculate general
cardiovascular disease (CVD) risk and risk of individual CVD events [7]. These models all use common
clinical and demographic variables to predict the prognosis of CHF patients and have convenient online
calculators. Although these scores have been validated, they have not been widely adopted possibly
because they are not routinely calculated in clinical practice [8–10], have poor reliability at the individual
patient level [11], suffer from a signi cant amount of missing data requiring imputation.
Metabolomics is a rapidly growing eld in biomarker pro ling that could help meet the need for more
robust prognostic biomarkers. By applying nuclear magnetic resonance (NMR) spectroscopy and mass
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spectrometry (MS), it is now possible to analyze a hundreds of metabolites from human samples such as
blood, urine, saliva, and tissue, which can elucidate the outcome of complex networks of endogenous and
exogenous biochemical reactions [12]. This approach could provide a more comprehensive signature of
biochemical activities that could be associated with diet, medication, disease progression, and thus
negative outcomes due to these complex mechanisms [13, 14]. Previous studies have shown that
metabolomic biomarkers can be used for risk prediction as well as diagnosis of CHF [15–27].
One promising metabolomic biomarker panel in CHF patients is the cardiac lipid panel (CLP) which is
supplemented by N-terminal pro–B-type natriuretic peptide (NT-proBNP). The CLP is consists of three
speci c metabolomics features: triacylglycerol (TAG) 18:1/18:0/18:0, phosphatidylcholine (PC)
16:0/18:2, and the sum of the 3 isobaric sphingomyelin (SM) species SM d18:1/23:1, SM d18:2/23:0,
and SM d17:1/24:1. The diagnostic value of CLP was rst discovered in a study by Mueller and
colleagues, where they compared CHF patients to healthy controls, and found that CLP was able to
improve the diagnostic performance over NT-proBNP alone [28]. The incremental prognostic value of the
CLP was rst assessed in a recent study which found it improved the discrimination and risk assessment
over NT-proBNP and clinical risk factors [29].
The objective of this study was to compare the performance of a risk score composed of the CLP panel
plus NT-proBNP to the three commonly used traditional risk scores (SHFM, FRS, and MAGGIC) to predict
long-term cardiovascular mortality in ambulatory CHF patients. We hypothesized that the CLP risk score
would improve our ability to classify risk of cardiovascular death in comparison to the three validated
clinical risk prediction algorithms.

Results
Table 1 shows the baseline characteristics of the total population (n = 280) as well as the variables
included in each score. Mean age of this sub-cohort was 72.1 (4.9) years, 26.4% were women, 45%
patients had heart failure with reduced ejection fraction (HFrEF) (LVEF < 35%), and most patients were in
NYHA functional class II (67.5%) with the remaining in NYHA class III. Hypertension was present in 80%
of participants and 45% were current or former smokers; 29% had diabetes and 71% had CAD. During the
follow-up period (mean = 81 months, SD = 33; median = 96 months), 95 (34%) patients met the primary
outcome. The sample selection criteria as well as the comparison of this sub cohort’s baseline
characteristics to the source cohort has previously been reported [29], however, this study analyzed
10 year follow up rather than the previously reported 4 year follow up.
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Table 1
Baseline characteristics of the study participants and variables included in each prognostic score
Total

Prognostic Score

Characteristic

n = 280

SHFM

FRS

MAGGIC

Age (years), mean ± SD

72 ± 4.9

✓

✓

✓

NYHA (II/III), n

188/91

✓

Male, n (%)

206 (74)

✓

Body mass index (kg/m2), mean ± SD

26.8 ± 3.4

Heart rate (bpm), mean ± SD

73 ± 13.0

Systolic blood pressure (mm Hg), mean ±
SD

134 ± 19

Diastolic blood pressure (mm Hg), mean ±
SD

81 ± 11

Years since rst diagnosis of CHF

5.2 ± 5.6

CLP

✓
✓

✓
✓

✓

✓

✓

✓

Laboratory, mean ± SD
Creatinine (µmol/L)

107 ± 27.9

Hemoglobin (g/dL)

21.6 ± 2.4

✓

Sodium (mEq/L)

141.4 ± 3.3

✓

Uric acid (µmol/L)

356 ± 127

✓

Total Cholesterol (mmol/L)

5.1 ± 1.6

HDL cholesterol (mmol/L)

1.2 ± 0.5

LDL cholesterol (mmol/L)

3.4 ± 1.3

Triglycerides (mmol/L)

1.7 ± 1.0

Lymphocytes (%)*

✓

✓

✓

NT-proBNP (pg/mL)

793 (331–1765)†

✓

PC 16:0/18:2 (µg/dl)

36810 (32435–
40015)†

✓

TAG 18:2 (µg/dl)

121 (76.5-256.4)†

✓

SM d18:1/23:1, SM d18:2/23:0, SM
d17:1/24:1 (µg/dl)

1342 (1134–
1596)†

✓

Cardiac Imaging, mean ± SD
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Total

Prognostic Score

LVEF (%)

36 ± 9.5

✓

LVDed (mm)

58.8 ± 9.2

LVDes (mm)

45.5 ± 9.7

LVVed (mL)

152.7 ± 63.9

LVVes (mL)

101.1 ± 51.6

LAes (mm)

45.3 ± 7.2

E/e'

12 ± 9.2

E/A

1 ± 0.8

Deceleration time (ms)

226 ± 80

✓

Comorbidities, n (%)
Diabetes

82 (29)

Hypertension

224 (80)

Coronary artery disease

200 (71)

Smokers

125 (45)

Hyperlipidemia

162 (58)

COPD

9 (3)

✓

✓

✓

✓

✓

✓

Medication, n (%)
ACE inhibitor

247 (88)

✓

Allopurinol

0 (0)

✓

ARB

115 (41)

✓

Beta Blocker

203 (73)

✓

Diuretics

219 (78)

Diuretic Dose mg/kg per day

0.32 ± 0.31

Glycoside

59 (21)

Aspirin

216 (77)

Nitrate

146 (52)

Antiarrhythmic agent

42 (15)

Statin

114 (41)
Page 6/22

✓

✓

✓

✓

Total

Prognostic Score

Caption:
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CE 18:2, triacylglycerol
18:1/18:0/18:0; COPD, chronic obstructive pulmonary disease; E/A, ratio of the early (E) to late (A)
ventricular lling velocities; E/e', ratio between early mitral in ow velocity and mitral annular early
diastolic velocity; LAes, left atrial end systole; LDL, low-density lipoprotein; NYHA, New York Heart
Association; HDL, high-density lipoprotein; LVDed, left ventricular diameter end diastole; LVDes, left
ventricular diameter end systole; LVVed, left ventricular volume end diastole; LVEF, left ventricular
ejection fraction; LVVes, left ventricular volume end systole; mg/kg, milligrams per kilograms; NTproBNP, N-terminal pro–B-type natriuretic; PC 16:0/18:2, phosphatidylcholine 16:0/18:2; SM d18:1/23:1,
SM d18:2/23:0, SM d17:1/24:1, the sum of the 3 isobaric sphingomyelin species SM d18:1/23:1, SM
d18:2/23:0, and SM d17:1/24:1
*Imputed using the median, 31%, of the normal range 20–40%
† Median (Interquartile Range)
All variables were available for each score except for the lymphocytes (%) variable in the SHFM score,
which was imputed as previously described. The SHFM model had the highest number of variables (n =
17), followed by MAGGIC (n = 13), FRS (n = 7), and CLP (n = 4). There were 10 overlapping variables which
were included in at least 2 scores. The SHFM score included the most medication (n = 6) and laboratory
(n = 5) variables while MAGGIC included the most clinical (n = 7) and demographic variables (n = 3).
Table 2 shows the univariate Cox Regression results. The CLP (HR = 2.38, p < 0.001), SHFM (HR = 2.01, p
= 0.002, and MAGGIC (HR = 1.10, p < 0.001) scores were signi cantly associated with the outcome while
FRS was not. Figure 1 shows the AUC change over time (IAUC) for the 4 prognostic scores with the
comparison of Uno’s concordance statistics for hypothesis testing. The IAUC was 0.53, 0.61, 0.68 and
0.78 for FRS, SHFM, MAGGIC and CLP, respectively. Harrell’s c statistics at 10 year follow up show similar
results (Supplemental Table 1). The three traditional scores were all signi cantly different (p < 0.001)
from the CLP score according to Uno’s difference in concordance statistic (Supplemental table 2).
Table 2
Prognostic Scores and Univariate Hazard Ratios
Score

HR (95% CI)

p value

SHFM

2.01 (1.29–3.13)

0.0022

FRS

1.02 (0.97–1.07)

0.5291

MAGGIC

1.10 (1.05–1.14)

< .0001

CLP

2.38 (1.95–2.92)

< .0001

Caption: Unadjusted Cox proportional hazard models of 10-year outcome for cardiovascular mortality.
Total subjects, n = 280. Total events, n = 95. SHFM (Seattle Heart Failure Model), FRS (Framingham
Risk Score), and MAGGIC (Meta-analysis Global Group in Chronic Heart Failure), and Cardiac Lipid
Panel Risk Score (CLP).
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Figure 2 shows the hierarchical cluster dendrogram mapped to illustrate the assignment of patients into
their respective clusters and the associated color map shows the range of each prognostic score and their
distribution within each cluster. Hierarchical clustering grouped the patients in separate clusters
accounting for the noise between smaller clusters. Each observation was treated as a unique cluster, and
this method: (1) identi ed the two similar or close clusters, and (2) merged the two most similar clusters.
Using this clustering technique, similar prognostic score data from participants were grouped together,
such that the members in the same group were more similar to each other than the members in the other
groups. We can infer from the cluster centres and cluster memberships that CLP risk score was better at
grouping patients with respect to their cardiovascular mortality risk and associated clinical
characteristics compared to the other three scores. The survival curves for each risk cluster are shown in
Fig. 3. Rates of mortality were: low risk cluster (23%), moderate risk cluster (41%) and high-risk cluster
(54%). Supplemental Fig. 1 shows the constellation plot on a two-dimensional plane with nodes and links
to describe relationship among component nodes. This plot is an alternate depiction of the dendrogram
and illustrates the length between clusters and a balanced structure. Supplemental Fig. 2 shows the
scatterplot matrix of all 4 scores and clusters to illustrate the relationships between each prognostic
score and risk cluster assignment.
Table 3 shows the cohort characteristics and the prognostic score distribution for each risk cluster. The
three clusters were: low risk, n = 148; moderate risk, n = 74; high risk, n = 58. Most characteristics were
different across risk clusters, with 28 out of the 50 cohort characteristics signi cantly different across the
3 clusters. In particular, patients in the highest risk cluster were older, with lower LVEF, higher NT-proBNP,
and experienced a higher frequency of events. All prognostic scores were signi cantly different across
their respective risk clusters. Of the continuous risk scores (FRS, SHFM, MAGGIC), only FRS had its
highest mean score in the high-risk cluster. The categorical CLP score showed a skewed distribution of
higher risk scores (3–4) in the moderate and high-risk clusters. In the high-risk cluster, the majority of
subjects were scored with highest possible CLP score of 4.
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Table 3
Comparison of Cohort Characteristics and Prognostic Scores
Cluster 1

Cluster 2

Cluster 3

p-value

Low Risk

Moderate Risk

High Risk

Characteristic

n = 148

n = 74

n = 58

Age (years), mean ± SD

71 ± 4.2

73 ± 4.9

74 ± 5.2

< .0001a

NYHA (II/III), n

121/26

47/27

20/38

< .0001c

Male, n (%)

95 (64)

64 (87)

47 (81)

0.0005b

Body mass index (kg/m2), mean ±
SD

27.3 ± 3.5

26.7 ± 3.2

25.9 ± 3.6

0.0620a

Heart rate (bpm), mean ± SD

73 ± 12.6

73.1 ± 11.6

74.5 ± 15.4

0.9746a

Systolic blood pressure (mm Hg),
mean ± SD

138.5 ± 21.5

132.4 ± 14.2

125.2 ± 13.6

< .0001a

Diastolic blood pressure (mm Hg),
mean ± SD

82.6 ± 12.3

80.1 ± 9.7

77.3 ± 8.5

0.0133a

Years since rst diagnosis of CHF

5.5 ± 5.8

4.7 ± 4.8

5.1 ± 6.2

0.6249a

Cardiac Death, n (%)

34 (23)

30 (41)

31 (54)

0.0001b

Serum creatinine (µmol/l)

99.4 ± 24

109.4 ± 22.9

122.9 ± 34.9

< .0001a

Hemoglobin (g/dL)

21.6 ± 2.2

21.7 ± 2.8

21.2 ± 2.4

0.1927a

Sodium (mmol/L)

141.9 ± 3.1

140.5 ± 3.6

141.5 ± 3.0

0.0428a

Uric acid (µmol/L)

327.7 ± 116.7

384.6 ± 119

383.4 ± 138.6

0.0007a

Total Cholesterol (mmol/L)

5.3 ± 1.6

5.0 ± 1.5

4.7 ± 1.6

0.0271a

HDL cholesterol (mmol/L)

1.3 ± 0.5

1.2 ± 0.4

1.1 ± 0.3

0.0441a

LDL cholesterol (mmol/L)

3.6 ± 1.3

3.5 ± 1.3

3.0 ± 1.2

0.0105a

Triglycerides (mmol/L)

1.8 ± 1.1

1.7 ± 1.9

1.6 ± 0.8

0.5955

Lymphocytes (%)*

31

31

31

N/A

NT-proBNP (pg/mL)

506.3 (307–
1228)†

985.1 (346–
1935)†

1453 (609–
3704)†

< .0001a

Laboratory, mean ± SD
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Cluster 1

Cluster 2

Cluster 3

Low Risk

Moderate Risk

High Risk

PC 16:0/18:2 (µg/dl)

36975
(33143–
40948)†

36550
(32575–
39015) †

34840
(29710–
38818) †

0.0252

TAG 18:2 (µg/dl)

126 (73–
272)†

120 (90–182)

97.8 (64–275)

0.5915

SM d18:1/23:1, SM d18:2/23:0,
SM d17:1/24:1 (µg/dl)

1432 (1212–
1699)†

1233 (1080–
1490) †

1256 (1046–
1361) †

< .0001a

LVEF (%)

39.4 ± 9.2

33.8 ± 7.9

30.0 ± 8.4

< .0001a

LVDed (mm)

57.4 ± 8.6

59.7 ± 9.2

61.5 ± 9.9

0.0094a

LVDes (mm)

43.5 ± 8.8

47.1 ± 9.7

48.5 ± 10.6

0.0021a

LVVed (mL)

140.7 ± 56.2

160.1 ± 74.3

173 ± 62.3

0.0017a

LVVes (mL)

88 ± 43.3

111 ± 58.8

120.8 ± 52.6

< .0001a

LAes (mm)

44.2 ± 6.7

45.4 ± 7.4

47.7 ± 7.7

0.0146a

E/e'

11.3 ± 8.0

11.1 ± 7.6

14.2 ± 13.2

0.2632a

E/A

0.9 ± 0.6

1.2 ± 0.9

1.3 ± 0.8

0.0922a

Deceleration time (ms)

235.6 ± 80.7

221 ± 63.7

210.8 ± 90.8

0.0572a

Diabetes

28 (19)

34 (46)

20 (35)

0.0001b

Hypertension

119 (80)

62 (84)

43 (74)

0.3823b

Coronary artery disease

95 (64)

58 (78)

47 (81)

0.0168b

Smokers

48 (32)

53 (71)

24 (41)

< .0001b

Hyperlipidemia

87 (59)

43 (58)

32 (55)

0.8716b

COPD

5 (3)

4 (5)

0 (0)

0.2143

132 (89)

66 (89)

49 (84)

0.6127b

†

†

p-value

a

a

Cardiac Imaging, mean ± SD

Comorbidities, n (%)

Medication, n (%)
ACE inhibitor
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Cluster 1

Cluster 2

Cluster 3

p-value

Low Risk

Moderate Risk

High Risk

Allopurinol

0 (0)

0 (0)

0 (0)

N/A

ARB

55 (37)

30 (41)

30 (52)

0.1602b

Beta Blocker

123 (83)

48 (65)

32 (55)

< .0001b

Diuretics

36 (24)

14 (19)

11 (19)

0.5523b

Diuretic Dose mg/kg, mean ± SD

0.26 ± 0.26

0.36 ± 0.34

0.41 ± 0.34

0.0033a

Glycoside

29 (20)

15 (21)

15 (26)

0.5996b

Aspirin

117 (79)

58 (78)

41 (71)

0.4189b

Nitrate

74 (50)

41 (55)

31 (54)

0.7307b

Antiarrhythmic agent

19 (13)

10 (14)

13 (22)

0.2048b

Statin

62 (42)

27 (37)

25 (43)

0.6804b

SHFM, Mean (SD)

0.67 ± 0.45

1.4 ± 0.31

0.60 ± 0.36

< .0001a

FRS, Mean (SD)

20.5 ± 4.3

19.5 ± 3.7

21.8 ± 3.8

0.0392a

MAGGIC, Mean (SD)

21.3 ± 4.0

28.3 ± 3.3

21.3 ± 4.6

< .0001a

Prognostic Scores

CLP, n (%)

< .0001b

0

31 (94)

2 (6)

0 (0)

1

105 (88)

14 (12)

0 (0)

2

10 (44)

9 (39)

4 (17)

3

2 (2)

40 (47)

44 (51)

4

0 (0)

9 (47)

10 (53)

Caption:
Cohort characteristics and prognostic score distribution across risk clusters. The prognostic scores
used for clustering were: SHFM (Seattle Heart Failure Model), FRS (Framingham Risk Score), and
MAGGIC (Meta-analysis Global Group in Chronic Heart Failure), and Cardiac Lipid Panel Risk Score
(CLP). Each prognostic score was standardized to the same scale (mean = 0; SD = 1). Ward’s
minimum variance method was used for clustering.
Abbreviations:
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Cluster 1

Cluster 2

Cluster 3

Low Risk

Moderate Risk

High Risk

p-value

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CE 18:2, triacylglycerol
18:1/18:0/18:0; COPD, chronic obstructive pulmonary disease; E/A, ratio of the early (E) to late (A)
ventricular lling velocities; E/e', ratio between early mitral in ow velocity and mitral annular early
diastolic velocity; LAes, left atrial end systole; LDL, low-density lipoprotein; NYHA, New York Heart
Association; HDL, high-density lipoprotein; LVDed, left ventricular diameter end diastole; LVDes, left
ventricular diameter end systole; LVVed, left ventricular volume end diastole; LVEF, left ventricular
ejection fraction; LVVes, left ventricular volume end systole; mg/kg, milligrams per kilograms; NTproBNP, N-terminal pro–B-type natriuretic; PC 16:0/18:2, phosphatidylcholine 16:0/18:2; SM d18:1/23:1,
SM d18:2/23:0, SM d17:1/24:1, the sum of the 3 isobaric sphingomyelin species SM d18:1/23:1, SM
d18:2/23:0, and SM d17:1/24:1
a

Wilcoxon rank sum test, bPearson’s chi-square test, cMantel-Haenszel chi-square.

*Imputed using the median, 31%, of the normal range 20–40%
† Median (Interquartile Range)
The correlation of the CLP biomarkers TAG, PC, and SM were most correlated with the clinical
characteristics triglycerides (r = 0.531, p < 0.001), total cholesterol (r = 0.431, p < 0.001), and LDL (r=, 0.502,
p < 0.001), respectively (Supplemental Fig. 3).

Discussion
We found that a risk score based on a novel panel of three metabolite-based biomarkers plus NT-proBNP
outperformed commonly used traditional prognostic models for predicting cardiovascular mortality in
elderly ambulatory CHF patients. We rst measured the association of each risk score with the outcome,
followed by discrimination analysis, then cluster analysis to support the discrimination ndings, and
nally correlation analysis of the individual CLP biomarkers with the clinical characteristics. In our study
cohort, CLP score, showed the best discrimination compared to the other 3 scores. This indicates that the
biomarker information included in the CLP score could more precisely classify high risk CHF patients
than the information included in the 3 other risk scores. On the other hand, the biomarker information
from the CLP is not as easily attainable and no convenient calculator exists yet, as these ndings should
rst be validated in larger cohorts. Nevertheless, the other risk scores may be improved with the addition
of common biomarkers in their score calculation. For instance, NT-proBNP is a well-established biomarker
that is known to be associated with ventricular wall stress [43] and is considered the gold-standard
biomarker in CHF diagnosis and prognosis [44]. None of the other prognostic scores included NT-proBNP
in their risk score calculation.
We performed cluster analysis to assess how well the risk scores could partition subjects into different
risk groups, blinded to the study outcome. A strength of this approach is that clusters could de ne
relevant groups of patients and could mitigate the problems of multicollinearity while determining if the
predictive variables are useful in separating these groups. In our study, patients within each cluster varied
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considerably along measures of age, comorbidities, laboratory parameters, as well as the prognostic
scores. Several prior studies have used similar clustering methods to identify clinically relevant patient
subgroups for CHF [41, 42], but we are not aware of previous studies using clustering methods to
compare a novel biomarker score to other conventional prognostic scores for CHF.
The combination of the CLP’s metabolomic features with NT-proBNP into a risk score may help overcome
limitations of using only traditional clinical risk factors. Furthermore, application of a single biomarker
such as NT-proBNP for outcome prediction is limited by insu cient speci city (low predictive value or
high false positive rate) [45, 46]. Recently, it was reported that the CLP added incremental prognostic
value to NT-proBNP in predicting 4-year cardiovascular mortality [29]. We used the same method to
calculate the CLP score for this study, as we were not interested in the CLP’s incremental value to NTproBNP, rather the comparison of the CLP score to other established prognostic score. A recent metaanalysis of 18 metabolomic prognostic biomarker studies for CVD found those which incorporated a
selection of metabolites into a score (n = 5 studies) had the best prognostic performance rather than
using the individual biomarker values [15]. Another systematic review [19] reported 6 studies [20–25]
developed a metabolite-based score to predict CVD risk with each score composed between 4 and 16
biomarkers.
In addition to improving risk prediction, developing a biomarker-based risk score could also improve our
understanding of the pathophysiology and biological mechanisms involved in CHF. The CLP metabolites
can be grouped into three different lipid subclasses, sphingomyelin (SM) phosphatidylcholine (PC), and
triglycerides (TAG), which have previously been found to be associated with cardiomyocyte
stress/apoptosis [47], intestinal microbial metabolism/in ammation [18], and coronary artery disease
[48], respectively. The ndings in this study showed that the individual CLP metabolites were correlated
with traditional lipid measures; the sphingomyelin metabolite was correlated with LDL,
phosphatidylcholine with total cholesterol, and triacylglycerol with total triglycerides. Future studies are
needed to establish whether the CLP biomarkers are characteristic of altered biological pathways or are
representative of CHF compensation mechanisms.

Study Limitations
The homogeneity of this cohort, elderly patients with stable CHF, may have had an impact on the
performance of the prognostic scores. The SHFM score may have been affected by the imputation of
lymphocytes % as well as the lack of patients taking allopurinol. The FRS was originally developed for
coronary artery disease and not CHF, which may explain its poor performance on this cohort. The CLP
biomarker kit was developed for routine use in the clinic; however, it is still a research biomarker panel
pending regulatory approval and must be sent to a lab equipped with MS technology. Our ndings are
limited to this population of elderly CHF patients and future validation studies should be performed to
include a more heterogenous cohort such as younger, more women, and early/ asymptomatic patients.
Other common biomarkers such as ST2, hs-CRP, and troponins should be compared to the CLP as they
are more readily available and do not require samples be sent to a specialized lab. The CLP panel was
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originally developed as a diagnostic and early detection biomarker for HFrEF, and clinicians and
researchers should be cautious when using it as a prognostic tool, as these are still preliminary ndings.

Conclusion
In a cohort of ambulatory CHF patients, we have shown that the prognostic scores included in this study
were useful in stratifying patients into risk clusters. Our ndings demonstrate that the CLP risk score
comprising a panel of 3 novel metabolomic biomarkers and NT-proBNP, could improve the prediction of
cardiovascular mortality over traditional prognostic scores. In the future, a broader array of biomarkers
should be integrated into a more comprehensive risk score that may improve discrimination potential and
risk strati cation and the CLP offers a promise. The CLP score is a step in the direction of providing a
more precise decision support tool to assist clinicians and patients in managing their CHF treatment.

Methods
Study Population
This study used a sub-cohort randomly selected from the Cardiac Insu ciency Bisoprolol Study in Elderly
(CIBIS-ELD) trial, a multi-center, randomized, double-blind trial with ≥ 65-year-old patients being treated
for CHF. The original study design and results of the CIBIS-ELD trial have been published previously [30,
31]. Brie y, patients with CHF were randomized in a 1:1 fashion to receive two different beta-blockers,
either bisoprolol or carvedilol, and up titrated every fortnight for 12 weeks and then followed at 10 years.
From this source cohort (n = 883), there were n = 589 with available blood samples. Patients were
randomly selected and included in the analysis only if they passed quality control [32, 33] resulting in a
nal set of 280 cases. The ethics committees of all participating centers approved the study protocol, and
informed consent was signed by all participants prior to study participation. The ethics committees
include: Germany: Ethikkommission der Charité on the 13th June 2007 (Amendment 5) (ref: 125/2004),
Serbia: Ethics board of the University Hospital on the 31st March 2006 (ref: 6108/18), Slovenia: The
national medical ethics committee on the 2nd July 2007 (ref: KME 188/06/07). The investigation
conformed to the principles outlined in the Declaration of Helsinki [34].
Biomarker Measurements
Targeted metabolite pro ling of the serum samples which passed quality control was performed at a
specialized metabolomics lab using a commercially available kit. The kit uses a protocol based on a 1phase extraction of the blood samples followed by gas chromatography mass spectrometry (GC-MS)
(Agilent 6890 GC coupled to an Agilent 5973 MS-System) and liquid chromatography tandem-mass
spectrometry (LC-MS/MS) (Agilent 1100 HPLC-System coupled to an Applied Biosystems API4000
MS/MS-System) analysis as previously described [28]. The analytical protocol was designed for routine
measurement in the clinical practice setting; however, it is currently only available in specialized labs
equipped with MS technology. The samples were stored at − 80 °C and transferred on dry ice prior to
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analysis. The three CLP metabolomic features and NT-proBNP measurements, were generated at
baseline, only for the previously mentioned samples (n = 280). NT-proBNP was a measured using
commercially available assays (Elecsys, Roche Diagnostics).
Calculating Prognostic Scores
Each prognostic score was calculated using the corresponding method proposed by the original authors
(3–5). For calculating the SHFM score, % lymphocyte was missing, and the median (31%) of the normal
range (20–40%) was imputed for all subjects. The CLP risk score was calculated as the count of
biomarkers above the Youden index cut-off [35]. The Youden’s index calculates each biomarker’s optimal
cut-off from the Cox regression. There were 4 cut-off values, since four biomarkers are included in the
score: three from the CLP and NT-proBNP. Based on the cut-off, a value of 1 or 0 was assigned if the
biomarker value was above/below the cut-off value, or in the direction of greater risk, then all 4 values
were summed to generate the nal score for each subject. The score ranged from 0 to 4, higher scores
indicating higher risk. The primary outcome, cardiovascular death, was de ned as death by myocardial
infarction, non-responding arrhythmia, asystole, chronic pump failure, or other cardiac cause and veri ed
by a blinded committee of cardiologists.
Statistical Analysis
Power and Sample Size
The sample size was adjusted for an anticipated event rate of 0.34. A Cox regression of the log hazard
ratio on a covariate with a standard deviation of 1.5 based on a sample of 257 observations achieves
80% power at a 0.050 signi cance level to detect a regression coe cient equal to 0.2. Adjusting for an
anticipated loss to follow up rate of 10%, the nal sample size would be 283.
Discrimination Analysis
Categorical variables were expressed as number (%) and continuous variables were expressed as mean
(SD). Univariate Cox Regression was performed on each of the prognostic scores, and hazard ratios and
95% con dence intervals were calculated to assess their relationship with the outcome. For the survival
models, integrated area under the receiver operator curves (IAUC) and Harrell’s c statistic [36] calculated
to assess the discrimination of each score in predicting the outcome. Hypothesis testing of the change in
discrimination was performed by calculating the differences in Uno’s concordance statistics [37]. The
IAUC curves are computed as a weighted average of the AUC values at all the event times, with the
weights as the jumps of the Kaplan-Meier estimate of the survivor function
Cluster Analysis
Hierarchical cluster analysis was performed using Ward’s minimum variance method to assess each
prognostic score’s ability to separate cases into risk groups. The distance between two clusters is the
ANOVA sum of squares between the clusters summed over all variables. Only the 4 risk scores used as
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the input variables for the cluster analysis to examine how well they classi ed patients into a low,
moderate, and high-risk of cardiovascular mortality. Data was standardized (mean of 0 and SD of 1), to
perform clustering. The clinical characteristics and scores were compared across risk clusters.
Comparisons among continuous variables were performed using Wilcoxon rank sum test; and Pearson’s
chi-square test (or Fisher’s exact test) or Mantel-Haenszel Chi-square test for categorical and ordinal data,
respectively. Kaplan-Meier curves were used to compare the survival distribution across risk clusters.
Survival time was calculated from baseline until cardiovascular death or censoring at 10 year follow up.
Correlation Analysis
To investigate potential relationships between the CLP biomarker values and common clinical
parameters, Pearson’s correlation coe cients were calculated, signi cant at the 0.01 level (2-tailed). All
analyses were performed using SAS statistical software version 9.4 (SAS Institute, Inc., Cary, North
Carolina) and JMP pro software version 14, and R software version 3.6.1 [38–40].
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Figure 1
Discrimination Performance for each Prognostic Score for 10-year Cardiovascular Mortality Caption:
Integrated area under the curve (IAUC) for: SHFM (Seattle Heart Failure Model), FRS (Framingham Risk
Score), and MAGGIC (Meta-analysis Global Group in Chronic Heart Failure), and Cardiac Lipid Panel Risk
Score (CLP). Total subjects, n=280; total events, n=95. P-values were calculated from the differences in
Uno’s concordance statistic in comparison to the CLP score.
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Figure 2
Hierarchal Cluster Dendrogram of Three Risk Clusters Caption: Assignment of patients into risk clusters
based on the prognostic scores. The clustering process can be viewed by reading the dendrogram from
left to right. Each step consists of combining the two closest clusters into a single cluster. The joining of
clusters is indicated by horizontal lines that are connected by vertical lines. The horizontal position of the
vertical line represents the distance between the two clusters that are most recently joined to form the
speci ed number of clusters. The prognostic scores used for clustering were: SHFM (Seattle Heart Failure
Model), FRS (Framingham Risk Score), and MAGGIC (Meta-analysis Global Group in Chronic Heart
Failure), and Cardiac Lipid Panel Risk Score (CLP). Each prognostic score was standardized to the same
scale (mean=0; SD=1). Ward’s minimum variance method was used for clustering. Blue dendrogram
indicates the cluster 1 (low risk), n=148; Grey dendrogram indicates cluster 2 (moderate risk), n= 74. Red
dendrogram indicates cluster 3 (high risk), n= 58; Total subjects, n=280
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